{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Phase 1 trial sponsored by Kura Oncology, Inc. under Protocol Number KO-MEN-008 entitled Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed\/Refractory Acute Myeloid Leukemia. Attached for your consideration is a high-level overview of the trial.","item":"https:\/\/www.regionalcancercare.org\/trials\/phase-1-trial-sponsored-by-kura-oncology-inc-under-protocol-number-ko-men-008-entitled-phase-1-study-to-determine-the-safety-and-tolerability-of-ziftomenib-combinations-for-the-treatment-of-kmt2a-re\/#breadcrumbitem"}]}